Rapidly Identifying HCPs Treating AML: The Lab Data Advantage
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow,...
Unlocking Precision Targeting in Lysosomal Storage Disorders: How Prognos Health Empowers Commercial Teams
Lysosomal Storage Disorders (LSDs) present a unique challenge for pharmaceutical and biotech...
Decoding the Complexities of Breast Cancer Treatment: The Role of Lab Data & HCP Engagement
Breast cancer treatment is an intricate field, with ongoing research and development leading to...
Optimizing HCP Engagement: The Power of Timely, Precise, and Actionable Patient Alerts
Effective HCP engagement is a cornerstone of successful pharmaceutical marketing. The right...
Rare Disease Pharma: Navigating the DOJ's Sponsored Testing Ruling
The Department of Justice (DOJ) recently made waves in the pharmaceutical industry with a ruling...
Unveiling New Insights in NSCLC with Large-Scale FISH Panel Data
The landscape of Non-Small Cell Lung Cancer (NSCLC) treatment is constantly evolving, with...
Liquid Biopsies: A Game-Changer for Outreach to Healthcare Providers
In the fast-paced world of medicine, staying ahead of the curve is essential for pharmaceutical...
A shift to patient-first at Digital Pharma East
Like many life sciences marketing professionals in the life sciences and pharma industry, I...
.png)
Brand Eligible Patient Alerts Supercharge Marketing & Sales Execution
Q: What are alerts? Why are pharma brand teams using brand eligible patient alerts as part of...
The Challenges of Genomics Data for Rare Disease Patients
Niyati Parikh, Vice President, Clinical Solutions